Business
Virogentics Inc. Receives Report from Bulgarian Academy of Sciences Administration of ITV-1 to Begin First Week in June 2023
Virogentics Inc. Receives Report from Bulgarian Academy of Sciences Administration of ITV-1 to Begin First Week in June 2023.
About this update from Enzolytics Inc.
[{"type":"text","content":"COLLEGE STATION, TX / ACCESSWIRE / May 16, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced that the Company's wholly owned subsidiary, Virogentics (VIRO), has received the analysis report from the Bulgarian Academy of Sciences determining the protein concentration, native enzyme concentration and peptide analysis, and amino acid sequence for Module 3 for the permitting by the European Medicine agency ("EMA "). Receipt of this reportwill allow Virogentics to complete the cycle to fulfill the manufacturing conditions for production of the validation orders in mid-September of this year. Once manufacturing is complete the clinical trials for the EMA will begin in Germany by Korporativ Klinik Drug Research and Development. Once Module 3 is complete we will be formulating the requirements for Modules 4 and 5 for registration in Europe.The administration of the ITV-1 immunotherapy treatment, scheduled to begin during the first week of June 2023 under the supervision of Neuro Pharma Ltd - Rwanda, is being dispensed to volunteers under a fast-track protocol at HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC. VIRO is working with the hospitals on the protocols that will be used in the process. The impact of the treatment on the volunteers will be reported after the 17 week cycle is complete.IPF Immune was listed on the National Institutes of Health ("NIH") website under dietary supplement during May.Also, ENZC and SAGA are continuing to negotiate terms for the potential business combination taking into consideration the increase in ENZC's market value over the last few weeks since the initial disclosure of the transaction.Harry Zhabilov, CSO of VIRO and ENZC stated, "The continued development of the ITV-1 family of products and advances we are making toward distribution of our patented immunotherapy treatment to HIV patients in Africa, where the largest population of Aids victims resides, is more than I could have hoped."Enzolytics, Inc. OverviewEnzolytics, Inc. is a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat debilitating infectious diseases. The Company is advancing multiple therapeutics target...